ClinicalTrials.gg
CompletedNCT07076706Updated Mar 3, 2026

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

A Phase 2 interventional study of minoxidil + finasteride and minoxidil + finasteride in Male Pattern of Hair Loss, Androgenic Alopecia and Androgenetic Alopecia (AGA), sponsored by Beijing Dayspring Pharmaceutical Technology Co., Ltd. Completed at 8 sites in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Beijing Dayspring Pharmaceutical Technology Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
10th of 31
110 · median 60
Started
2024
with 1 other
Phase 2
6 of 31
1 open now
Registered
26th of 31
by date
Lead sponsor
1 of 31
Beijing Dayspring Pharmaceutical Technology Co., Ltd

Among the 31 studies testing minoxidil in Alopecia, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 2, and was the 26th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 74 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 46 (62%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

03

Conditions studied

  • Male Pattern of Hair Loss, Androgenic Alopecia
  • Androgenetic Alopecia (AGA)

Browse trials for

Keywords

  • minoxidil
  • finasteride
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria can be included in this study:

  1. Voluntarily sign the Form (ICF) approved by the Ethics Committee (IEC) before any study procedures begin. Participant who can understand and comply with the requirements of the protocol and agree to participate in all study visits;
  2. Male participant, aged 18 to 65 years (including the critical value) when signing the ICF;
  3. Participant diagnosed with androgenic alopecia, manifested as frontal hairline recession or hair loss in the vertex scalp area, corresponding to the Hamilton-Norwood classification diagnosis of grade III vertex type (i.e. grade IIIv), grade IV and grade V;
  4. Willing and able to complete all study assessments and comply with the protocol study schedule and restrictions, such as the participant is willing to shave the target evaluation area during the study, be marked by the researcher and maintain the same hair color;
  5. Participant agrees to use appropriate medical methods to avoid pregnancy in female partners from the signing of the ICF until 28 days after the last dose.

Exclusion criteria

Exclusion Criteria:

Before screening or administration, participants who meet any of the following criteria will not be included in this study:

  1. Allergic to any component of minoxidil, finasteride or (such as a history of alcohol allergy), or allergic constitution;
  2. According to the researcher's judgment, the participant's head has any of the following conditions that may interfere with the study evaluation:

    A. History of scalp skin abnormalities or scalp skin diseases, such as obvious dermatitis, trauma or infection near the administration site; B. White hair in the hair loss area that obviously interferes with the study evaluation; C. Secondary hair loss, such as hair loss caused by malnutrition, drugs, endocrine (hypothyroidism or hyperthyroidism, parathyroid or pituitary dysfunction), iron deficiency anemia and systemic lupus erythematosus; D. Hair loss caused by other reasons other than androgenic alopecia, such as alopecia areata, scarring alopecia, trichotillomania, telogen effluvium, or sudden increase in hair loss within 3 months before screening;

  3. Regarding the history of previous treatment, any of the following conditions may interfere with the study evaluation:

    A. Use of oral finasteride, dutasteride or similar products for androgenic alopecia within 1 year before screening; B. Use of topical minoxidil, local scalp radiation, phototherapy/laser or local injection of autologous -rich plasma (PRP) within 6 months before screening; C. Underwent general anesthesia within 3 months before screening; D. Use of systemic or topical scalp or synthetic steroids, or other drugs that affect androgenic alopecia within 4 weeks before screening or within 5 half-lives of the drug used (whichever is longer); E. Use of medical shampoos or solutions containing other ingredients such as ketoconazole or similar ingredients that may interfere with efficacy evaluation within 1 week before the first medication; F. Participants who have had hair transplantation, hair extensions or hair weaving before screening; or plan to have hair transplantation, hair extensions or hair weaving during the study treatment; or need to wear a wig for a long time; G. Participants who plan to use treatments related to hair growth and may affect prolactin levels; H. Participants who have used minoxidil regularly for ≥4 months but have not been effective; I. Participants who have received CG2001 treatment before.

  4. Other diseases with poorly controlled conditions that may affect the safety and efficacy evaluation of the trial drugs, such as malignant tumors, or poorly controlled diseases in the circulatory system, nervous system, blood system, digestive system (such as inflammatory bowel disease), immune system, mental system, etc. (except for completely resected carcinoma in situ, localized prostate cancer that has received radical treatment and has no disease recurrence, completely resected basal cell or squamous cell skin cancer, malignant melanoma with a complete remission time of more than 10 years, and other malignant tumors with a complete remission time of more than 5 years); or participants who plan to undergo surgery during the study; or within 3 months before screening, the weight loss exceeds 10% of their original body weight;
  5. Physical examination, vital signs, 12-lead (ECG), blood routine, urine routine, blood biochemistry, and sex hormone test results during the screening period are abnormal and (especially for participants with anemia), and the researchers judge that it will affect the safety assessment;
  6. History of drug abuse, alcoholism or drug abuse within 5 years before screening (Note: alcoholism includes binge drinking and heavy drinking. Binge drinking means that men drink 5 or more alcoholic drinks in about 2 hours at a time; heavy drinking or harmful drinking means that men drink 4 or more alcoholic drinks on any day, or the average daily alcohol intake of male drinkers is ≥61g; "cup" here means "standard cup", that is, 1 standard cup equals 10 grams of pure alcohol, 1 bottle of 750 ml wine is equivalent to 9 standard cups, 1 bottle of beer is equivalent to 2 standard cups, 1 bottle of 500 ml yellow wine (rice wine) is equivalent to 6 standard cups, 1 liang of 52-degree liquor is equivalent to 2 standard cups, 1 liang of 45-degree liquor is equivalent to 1.8 standard cups, 1 liang of 38-degree liquor is equivalent to 1.5 standard cups, and the number of grams of alcohol intake is equal to the number of milliliters of alcohol consumed × alcohol content × 0.8);
  7. Participated in or is participating in other interventional clinical trials (including drugs and medical devices) within 1 month before screening;
  8. The researcher believes that there are any other reasons that make the participants unsuitable for participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Minoxidil and low dose finasteride or placebo

    CG2001(5%minoxidil+0.075%finasteride) or placebo twice daily

    Drug: minoxidil + finasteride · Drug: Placebo foam

  • Experimental
    Minoxidil and high dose finasteride or placebo

    CG2001(5%minoxidil+0.1%finasteride) or placebo twice daily

    Drug: minoxidil + finasteride · Drug: Placebo foam

  • Experimental
    Minoxidil and low dose finasteride

    CG2001(5%minoxidil+0..075%finasteride) twice daily

    Drug: minoxidil + finasteride

  • Placebo comparator
    Placebo

    placebo

    Drug: Placebo foam

Interventions

  • Drugminoxidil + finasteride

    Drug pages: Minoxidil · Finasteride

    topical foam: 5%minoxidil+0.075%finasteride

  • Drugminoxidil + finasteride

    Drug pages: Minoxidil · Finasteride

    topical foam: 5%minoxidil+0.1%finasteride

  • DrugPlacebo foam

    Topical placebo foam

06

What researchers measure

Primary outcomes

  1. Change from baseline in the non-vellus target area hair count(TAHC) at 24 weeks

    Time frame: 24 weeks

Secondary outcomes

  1. Hair Growth Questionnaire

    Questionnaire assessing hair condition by participant. The score ranges from 7 to 38, higher scores mean a worse outcome.

    Time frame: 6, 12, 18, 24 weeks

  2. Participant self assessment of treatment satisfaction

    Treatment satisfaction will be measured with the "Patient Treatment-Effect Satisfaction Evaluation Form", a single-item, self-administered questionnaire with the score ranges from -3 to +3, where a higher score mean a highr satisfaction.

    Time frame: 6, ,12, 18, 24 weeks

  3. Investigator Global Assessment(IGA)

    Assessment made by investigator about the global condition of participant's hair. The value ranges from 0 to 4, higher score means a worse outcome.

    Time frame: 6, 12, 18, 24 weeks

  4. Change from baseline in non-vellus target area hair count(TAHC)

    Time frame: 6, 12, 18 weeks

  5. Change from baseline in Target Area Hair Width(TAHW)

    Target Area Hair Width (TAHW) is the cumulative hair diameter per unit area in the target area

    Time frame: 6, 12, 18, 24 weeks

  6. Change from baseline in terminal-vellus ratio

    Time frame: 6, 12, 18, 24 weeks

  7. Adverse events

    Time frame: up to 28 weeks

07

Study locations

8 sites
  • Beijing Tongren Hospital Affiliated to Capital Medical University
    Beijing, Beijing Municipality, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Jiangxi Provincial Dermatology Hospital
    Nanchang, Jiangxi, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Peking University People's Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2025, 8 months.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 41 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 22, 2025
StartActual
Dec 5, 2024
Primary completionActual
Aug 26, 2025
CompletionActual
Sep 23, 2025
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076706
Lead sponsor
Beijing Dayspring Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Dec 5, 2024
Primary completion
Aug 26, 2025
Completion
Sep 23, 2025
Last update
Mar 3, 2026

Study contacts

Jianzhong Zhang, MD, PhD
study chair · Peking University People's Hospital
Cheng Zhou, MD, PhD
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Minoxidil · Finasteride

Start the discussion